Angiotech follows a combinational route.
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Angiotech Pharmaceuticals |
American Medical Instruments |
$785 million cash buyout |
The deal expands Angiotech's drug development business with combinational devices and gives it a bigger sales force in the bargain. |
|
SuperGen |
Montigen |
$18M buyout |
Montigen's assets include its R&D team, a proprietary drug discovery technology platform and optimization process, and preclinical compounds targeting aurora-A kinase and members of the tyrosine kinase receptor family. |
|
GeoVax |
Dauphin Technology |
Merger |
Emory University emerges as the largest shareholder in venture aimed at developing an AIDS vaccine. |
|
Par Pharmaceutical |
FineTech Laboratories |
Divestiture |
FineTech has been transferred to Arie L. Gutman, Ph.D., president and CEO of FineTech. |
|
Clearview |
BioMachines |
Acquisition of majority control |
The deal is a vote of confidence in BioMachines' future in diagnostics. |
|
AngioGenex |
eClic |
Reverse merger |
The merger allows AngioGenex to go public. |